Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
Authors
Keywords
-
Journal
Medicina-Lithuania
Volume 55, Issue 7, Pages 336
Publisher
MDPI AG
Online
2019-07-03
DOI
10.3390/medicina55070336
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
- (2018) Ken Ohta et al. ALLERGOLOGY INTERNATIONAL
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide
- (2017) Rumi Kambara et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations
- (2017) Marina Pretolani et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
- (2017) Claus Bachert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study
- (2015) T. Tokunaga et al. ALLERGY
- Residual exhaled nitric oxide elevation in asthmatics is associated with eosinophilic chronic rhinosinusitis
- (2015) Yoshiki Kobayashi et al. JOURNAL OF ASTHMA
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma
- (2013) Michael E. Wechsler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
- (2011) Philippe Gevaert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Exhaled Nitric Oxide Cutoff Values for Asthma Diagnosis According to Rhinitis and Smoking Status in Japanese Subjects
- (2011) Kazuto Matsunaga et al. ALLERGOLOGY INTERNATIONAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started